Main > ONCOLOGY (**) > Lung>NSCLC>Stage III>MET>PD-L1+>> > TREAT.: > Co: USA. M. PembrolizuMAb



Co: USA. M. PembrolizuMAb's subsections
(*) USA Approval Date: 2019. 04.11.
>MonoTherapy
>Not Abnormal “EGFR” or “ALK" Gene
>Not Candidates for Surgical Resect
Company
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 4
Patent>UpDate: 2018. 10.23.
TradeMark
TradeMark Web-Site

Co: USA. M. PembrolizuMAb's products
This section has no products